Vion develops and commercializes products for the treatment of cancer, including Cloretazine, an alkylating agent that is undergoing a Phase 3 trial for the treatment of relapsed acute myelogenous leukemia [AML], and a Phase 2 trial for the treatment of de novo poor-risk AML in previously untreated elderly patients; and Triapine, a small molecule for the prevention of the replication of tumor cells.
The company has a tiny market cap of only $147 million. It has almost $80 million in cash and more than $50 million in debt according to the latest Yahoo! financial data.
Shares of Vion closed at $2.02 on Tuesday, 12% below the 52-week high of $2.30.
Vion has made BHI's BioWatch Alert List, and will be tracked for the next two weeks.